{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T04:33:24Z","timestamp":1711514004299},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,5,5]],"date-time":"2010-05-05T00:00:00Z","timestamp":1273017600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s00345-010-0558-y","type":"journal-article","created":{"date-parts":[[2010,5,4]],"date-time":"2010-05-04T09:05:12Z","timestamp":1272963912000},"page":"311-317","source":"Crossref","is-referenced-by-count":2,"title":["Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients"],"prefix":"10.1007","volume":"28","author":[{"given":"Philipp","family":"Ivanyi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anika","family":"Gro\u00dfhennig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel S.","family":"Merseburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,5]]},"reference":[{"key":"558_CR1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125\u2013134","journal-title":"N Engl J Med"},{"key":"558_CR2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115\u2013124","journal-title":"N Engl J Med"},{"key":"558_CR3","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMra043172","volume":"353","author":"HT Cohen","year":"2005","unstructured":"Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353:2477\u20132490","journal-title":"N Engl J Med"},{"issue":"3","key":"558_CR4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00345-004-0466-0","volume":"23","author":"JS Lam","year":"2005","unstructured":"Lam JS, Leppert JT, Belldegrun AS, Figlin RA (2005) Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 23(3):202\u2013212","journal-title":"World J Urol"},{"key":"558_CR5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMe068263","volume":"356","author":"J Brugarolas","year":"2007","unstructured":"Brugarolas J (2007) Renal-cell carcinoma\u2013molecular pathways and therapies. N Engl J Med 356:185\u2013187","journal-title":"N Engl J Med"},{"issue":"11","key":"558_CR6","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1002\/cncr.21453","volume":"104","author":"WM Stadler","year":"2005","unstructured":"Stadler WM (2005) Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 104(11):2323\u20132333","journal-title":"Cancer"},{"key":"558_CR7","first-page":"232","volume":"105","author":"P Ivanyi","year":"2008","unstructured":"Ivanyi P, Winkler T, Ganser A et al (2008) Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib. Dtsch Arztebl Int 105:232\u2013237","journal-title":"Dtsch Arztebl Int"},{"key":"558_CR8","first-page":"129","volume":"32","author":"V Grunwald","year":"2009","unstructured":"Grunwald V, Soltau J, Ivanyi P et al (2009) Molecular targeted therapies for solid tumors: management of side effects. Onkologie 32:129\u2013138","journal-title":"Onkologie"},{"key":"558_CR9","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdn168","volume":"19","author":"ML Telli","year":"2008","unstructured":"Telli ML, Witteles RM, Fisher GA, Srinivas S (2008) Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 19:1613\u20131618","journal-title":"Ann Oncol"},{"key":"558_CR10","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","volume":"26","author":"M Schmidinger","year":"2008","unstructured":"Schmidinger M, Zielinski CC, Vogl UM et al (2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204\u20135212","journal-title":"J Clin Oncol"},{"key":"558_CR11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.12.11.1","volume":"11","author":"MH Cohen","year":"2005","unstructured":"Cohen MH, Johnson JR, Pazdur R (2005) U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 11:12\u201319","journal-title":"Clin Cancer Res"},{"key":"558_CR12","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkela","year":"2006","unstructured":"Kerkela R, Grazette L, Yacobi R et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908\u2013916","journal-title":"Nat Med"},{"key":"558_CR13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2141.2004.04833.x","volume":"125","author":"I Isshiki","year":"2004","unstructured":"Isshiki I, Yamaguchi K, Okamoto S (2004) Interstitial pneumonitis during imatinib therapy. Br J Haematol 125:420","journal-title":"Br J Haematol"},{"key":"558_CR14","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","volume":"354","author":"E Berman","year":"2006","unstructured":"Berman E, Nicolaides M, Maki RG et al (2006) Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354:2006\u20132013","journal-title":"N Engl J Med"},{"key":"558_CR15","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1056\/NEJMc062388","volume":"355","author":"A Grey","year":"2006","unstructured":"Grey A, O\u2019Sullivan S, Reid IR, Browett P (2006) Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med 355:2494\u20132495","journal-title":"N Engl J Med"},{"key":"558_CR16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1056\/NEJMc061565","volume":"355","author":"S Owen","year":"2006","unstructured":"Owen S, Hatfield A, Letvak L (2006) Imatinib and altered bone and mineral metabolism. N Engl J Med 355:627","journal-title":"N Engl J Med"},{"key":"558_CR17","first-page":"628","volume":"355","author":"H Joensuu","year":"2006","unstructured":"Joensuu H, Reichardt P (2006) Imatinib and altered bone and mineral metabolism. N Engl J Med 355:628","journal-title":"N Engl J Med"},{"key":"558_CR18","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1210\/jc.2008-2324","volume":"94","author":"S O\u2019Sullivan","year":"2009","unstructured":"O\u2019Sullivan S, Horne A, Wattie D et al (2009) Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 94:1131\u20131136","journal-title":"J Clin Endocrinol Metab"},{"key":"558_CR19","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1359\/jbmr.070719","volume":"22","author":"S O\u2019Sullivan","year":"2007","unstructured":"O\u2019Sullivan S, Naot D, Callon K et al (2007) Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 22:1679\u20131689","journal-title":"J Bone Miner Res"},{"key":"558_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341","journal-title":"Nephron"},{"key":"558_CR21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(09)60507-9","volume":"374","author":"WD Fraser","year":"2009","unstructured":"Fraser WD (2009) Hyperparathyroidism. Lancet 374:145\u2013158","journal-title":"Lancet"},{"key":"558_CR22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1590\/S0004-27302006000400006","volume":"40","author":"MJ Seibel","year":"2006","unstructured":"Seibel MJ (2006) Clinical application of biochemical markers of bone turnover. Arq Bras Endocinol Metab 40:603\u2013619","journal-title":"Arq Bras Endocinol Metab"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-010-0558-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-010-0558-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-010-0558-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T01:02:39Z","timestamp":1685581359000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-010-0558-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,5]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["558"],"URL":"https:\/\/doi.org\/10.1007\/s00345-010-0558-y","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,5]]}}}